[go: up one dir, main page]

SV2002000179A - Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el - Google Patents

Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el

Info

Publication number
SV2002000179A
SV2002000179A SV2000000179A SV2000000179A SV2002000179A SV 2002000179 A SV2002000179 A SV 2002000179A SV 2000000179 A SV2000000179 A SV 2000000179A SV 2000000179 A SV2000000179 A SV 2000000179A SV 2002000179 A SV2002000179 A SV 2002000179A
Authority
SV
El Salvador
Prior art keywords
risk
cancer
compound
preparation
reduce
Prior art date
Application number
SV2000000179A
Other languages
English (en)
Inventor
Janet M Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2002000179A publication Critical patent/SV2002000179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE METODOS PARA DISMINUIR EL RIESGO DE CANCER MEDIANTE LA ADMINISTRACION DE UNA HORMONA PARATIROIDES. MAS PARTICULARMENTE, LOS METODOS DESCRITOS ESTAN DESTINADOS A DISMINUIR EL RIESGO DE CANCER EN UNA PERSONA CON RIESGO DE CONTRAER LA ENFERMEDAD, INCLUYENDO PERSONAS CON UN RIESGO RELATIVAMENTE BAJO DE OSTEOPOROSIS O CON ALTO RIESGO DE CONTRAER LA ENFERMEDAD O QUE YA LA PRESENTAN. LOS METODOS SON PARTICULARMENTE EFECTIVOS PARA DISMINUIR LOS RIESGOS DE CARCINOMA DE SENO O PIEL.
SV2000000179A 1999-09-20 2000-09-20 Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el SV2002000179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15545599P 1999-09-20 1999-09-20

Publications (1)

Publication Number Publication Date
SV2002000179A true SV2002000179A (es) 2002-07-16

Family

ID=22555504

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000179A SV2002000179A (es) 1999-09-20 2000-09-20 Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el

Country Status (11)

Country Link
US (1) US20050192227A1 (es)
EP (1) EP1221966B1 (es)
AR (1) AR025718A1 (es)
AT (1) ATE309820T1 (es)
AU (1) AU7363000A (es)
CA (1) CA2383574A1 (es)
DE (1) DE60024118T2 (es)
ES (1) ES2250187T3 (es)
PE (1) PE20010666A1 (es)
SV (1) SV2002000179A (es)
WO (1) WO2001021198A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CN113304250A (zh) 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1557176A1 (en) * 2004-01-26 2005-07-27 Ferring B.V. Treatment of bone metastases by means of PTH receptor agonists
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US20090042774A1 (en) * 2005-09-06 2009-02-12 Paul Morley Parathyroid hormone analogues and methods of use
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
KR20150116468A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
TW202535454A (zh) 2020-02-18 2025-09-16 丹麥商諾佛 儂迪克股份有限公司 醫藥配方

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
EP1166796A3 (en) * 1996-02-01 2002-03-06 Chugai Seiyaku Kabushiki Kaisha Agents for preventing and treating thrombocytopenia
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof

Also Published As

Publication number Publication date
AU7363000A (en) 2001-04-24
EP1221966B1 (en) 2005-11-16
AR025718A1 (es) 2002-12-11
DE60024118D1 (de) 2005-12-22
ES2250187T3 (es) 2006-04-16
ATE309820T1 (de) 2005-12-15
DE60024118T2 (de) 2006-07-27
US20050192227A1 (en) 2005-09-01
EP1221966A1 (en) 2002-07-17
CA2383574A1 (en) 2001-03-29
WO2001021198A1 (en) 2001-03-29
PE20010666A1 (es) 2001-06-20

Similar Documents

Publication Publication Date Title
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
NO20022065D0 (no) Terapeutisk anvendelse
RU2004136984A (ru) Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
DK1539184T3 (da) Östrogenerstatningsterapi
ES2077530A1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
IL146125A0 (en) Novel quinones as disease therapies
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
CY1108462T1 (el) Χρηση της αναστροζολης για τη θεραπευτικη αντιμετωπιση μετεμμηνοπαυσιακων γυναικων με καρκινο του μαστου σε πρωιμο σταδιο
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
BR0009771A (pt) Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
EA200200943A1 (ru) Гормональная терапия рака молочной железы
ES2138602T3 (es) Agente terapeutico para la amenaza de aborto.
PT1220676E (pt) Prevencao do cancro colorrectal
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
CY1109852T1 (el) Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη
ES2084995T3 (es) Composicion farmaceutica para el tratamiento de enfermedades malignas de los linfocitos b.
Brownlee et al. For every woman saved by breast cancer screening, thousands will have to undergo painful, traumatic even dangerous treatments they might never have needed. Is mammography the best way to save lives?
BR0314253A (pt) Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama
ES2163661T3 (es) Propanolol fluorado y metodos asociados.
AR018468A1 (es) Agente terapeutico antineoplasico de hexoxido de arsenido (as4o6) a partir de una sustancia quimica natural y su composicion farmaceutica